Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population.
DNA methylation
H3K27 trimethylation
Malignant peripheral nerve sheath tumors
Sarcoma classifier
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
received:
16
11
2023
accepted:
22
12
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
4
1
2024
Statut:
epublish
Résumé
Malignant peripheral nerve sheath tumors (MPNSTs) account for 3-10% of pediatric sarcomas, 50% of which occur in neurofibromatosis type 1 (NF1). Sporadic MPNSTs diagnosis may be challenging due to the absence of specific markers, apart from immunohistochemical H3K27me3 loss. DNA methylation (DNAm) profiling is a useful tool for brain and mesenchymal neoplasms categorization, and MPNSTs exhibit a specific DNAm signature. An MPNST-like group has recently been recognized, including pediatric tumors with retained H3K27me3 mark and clinical/histological features not yet well explored. This study aims to characterize the DNAm profile of pediatric/juvenile MPNSTs/MPNST-like entities and its diagnostic/prognostic relevance. We studied 42 tumors from two groups. Group 1 included 32 tumors histologically diagnosed as atypical neurofibroma (ANF) (N = 5) or MPNST (N = 27); group 2 comprised 10 tumors classified as MPNST-like according to Heidelberg sarcoma classifier. We performed further immunohistochemical and molecular tests to reach an integrated diagnosis. In group 1, DNAm profiling was inconclusive for ANF; while, it confirmed the original diagnosis in 12/27 MPNSTs, all occurring in NF1 patients. Five/27 MPNSTs were classified as MPNST-like: Integrated diagnosis confirmed MPNST identity for 3 cases; while, the immunophenotype supported the change to high-grade undifferentiated spindle cell sarcoma in 2 samples. The remaining 10/27 MPNSTs variably classified as schwannoma, osteosarcoma, BCOR-altered sarcoma, rhabdomyosarcoma (RMS)-MYOD1 mutant, RMS-like, and embryonal RMS or did not match with any defined entity. Molecular analysis and histologic review confirmed the diagnoses of BCOR, RMS-MYOD1 mutant, DICER1-syndrome and ERMS. Group 2 samples included 5 high-grade undifferentiated sarcomas/MPNSTs and 5 low-grade mesenchymal neoplasms. Two high-grade and 4 low-grade lesions harbored tyrosine kinase (TRK) gene fusions. By HDBSCAN clustering analysis of the whole cohort we identified two clusters mainly distinguished by H3K27me3 epigenetic signature. Exploring the copy number variation, high-grade tumors showed frequent chromosomal aberrations and CDKN2A/B loss significantly impacted on survival in the MPNSTs cohort. DNAm profiling is a useful tool in diagnostic work-up of MPNSTs. Its application in a retrospective series collected during pre-molecular era contributed to classify morphologic mimics. The methylation group MPNST-like is a 'hybrid' category in pediatrics including high-grade and low-grade tumors mainly characterized by TRK alterations.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant peripheral nerve sheath tumors (MPNSTs) account for 3-10% of pediatric sarcomas, 50% of which occur in neurofibromatosis type 1 (NF1). Sporadic MPNSTs diagnosis may be challenging due to the absence of specific markers, apart from immunohistochemical H3K27me3 loss. DNA methylation (DNAm) profiling is a useful tool for brain and mesenchymal neoplasms categorization, and MPNSTs exhibit a specific DNAm signature. An MPNST-like group has recently been recognized, including pediatric tumors with retained H3K27me3 mark and clinical/histological features not yet well explored. This study aims to characterize the DNAm profile of pediatric/juvenile MPNSTs/MPNST-like entities and its diagnostic/prognostic relevance.
RESULTS
RESULTS
We studied 42 tumors from two groups. Group 1 included 32 tumors histologically diagnosed as atypical neurofibroma (ANF) (N = 5) or MPNST (N = 27); group 2 comprised 10 tumors classified as MPNST-like according to Heidelberg sarcoma classifier. We performed further immunohistochemical and molecular tests to reach an integrated diagnosis. In group 1, DNAm profiling was inconclusive for ANF; while, it confirmed the original diagnosis in 12/27 MPNSTs, all occurring in NF1 patients. Five/27 MPNSTs were classified as MPNST-like: Integrated diagnosis confirmed MPNST identity for 3 cases; while, the immunophenotype supported the change to high-grade undifferentiated spindle cell sarcoma in 2 samples. The remaining 10/27 MPNSTs variably classified as schwannoma, osteosarcoma, BCOR-altered sarcoma, rhabdomyosarcoma (RMS)-MYOD1 mutant, RMS-like, and embryonal RMS or did not match with any defined entity. Molecular analysis and histologic review confirmed the diagnoses of BCOR, RMS-MYOD1 mutant, DICER1-syndrome and ERMS. Group 2 samples included 5 high-grade undifferentiated sarcomas/MPNSTs and 5 low-grade mesenchymal neoplasms. Two high-grade and 4 low-grade lesions harbored tyrosine kinase (TRK) gene fusions. By HDBSCAN clustering analysis of the whole cohort we identified two clusters mainly distinguished by H3K27me3 epigenetic signature. Exploring the copy number variation, high-grade tumors showed frequent chromosomal aberrations and CDKN2A/B loss significantly impacted on survival in the MPNSTs cohort.
CONCLUSION
CONCLUSIONS
DNAm profiling is a useful tool in diagnostic work-up of MPNSTs. Its application in a retrospective series collected during pre-molecular era contributed to classify morphologic mimics. The methylation group MPNST-like is a 'hybrid' category in pediatrics including high-grade and low-grade tumors mainly characterized by TRK alterations.
Identifiants
pubmed: 38178234
doi: 10.1186/s13148-023-01621-7
pii: 10.1186/s13148-023-01621-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Subventions
Organisme : Ministero della Salute
ID : 202005_ONCO_MIELE
Organisme : Ministero della Salute
ID : 202203_FBG_MILANO.1.15
Organisme : Ministero della Salute
ID : 202005_ONCO_ALAGGIO
Organisme : Fondazione AIRC per la ricerca sul cancro ETS
ID : IG_28768
Informations de copyright
© 2024. The Author(s).
Références
Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62(5):1573–7.
pubmed: 11894862
Ferrari A, Bisogno G, Carli M. Management of childhood malignant peripheral nerve sheath tumor. Pediatr Drugs. 2007;9(4):239–48.
doi: 10.2165/00148581-200709040-00005
Cleven AHG, Sannaa GAA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016;29(6):582–90.
doi: 10.1038/modpathol.2016.45
pubmed: 26990975
pmcid: 4948583
Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1227–32.
doi: 10.1038/ng.3095
pubmed: 25240281
pmcid: 4249650
Zhang M, Wang Y, Jones S, Sausen M, McMahon K, Sharma R, et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1170–2.
doi: 10.1038/ng.3116
pubmed: 25305755
pmcid: 4383254
Röhrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, et al. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol (Berl). 2016;131(6):877–87.
doi: 10.1007/s00401-016-1540-6
pubmed: 26857854
Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, et al. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;21(12):498.
doi: 10.1038/s41467-020-20603-4
Salgado CM, Alaggio R, Ciolfi A, Zin A, DiomediCamassei F, Pedace L, et al. Pediatric BCOR-altered tumors from soft tissue/kidney display specific DNA methylation profiles. Mod Pathol. 2023;36(2): 100039.
doi: 10.1016/j.modpat.2022.100039
pubmed: 36853789
Tian Y, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics. 2017;33(24):3982–4.
doi: 10.1093/bioinformatics/btx513
pubmed: 28961746
pmcid: 5860089
Hahsler M, Piekenbrock M, Doran D. dbscan: Fast Density-Based Clustering with R. J Stat Softw. 2019;31(91):1–30.
Jaffe AE, Murakami P, Lee H, Leek JT, Fallin MD, Feinberg AP, et al. Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol. 2012;41(1):200–9.
doi: 10.1093/ije/dyr238
pubmed: 22422453
pmcid: 3304533
Hovestadt V, Zapatka M. conumee: Enhanced copy-number variation analysis using Illumina DNA methylation arrays [Internet]. Bioconductor version: Release (3.17); 2023 [cited 2023 Oct 6]. Available from: https://bioconductor.org/packages/conumee/
Capper D, Stichel D, Sahm F, Jones DTW, Schrimpf D, Sill M, et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol (Berl). 2018;136(2):181–210.
doi: 10.1007/s00401-018-1879-y
pubmed: 29967940
Skidmore ZL, Wagner AH, Lesurf R, Campbell KM, Kunisaki J, Griffith OL, et al. GenVisR: genomic visualizations in R. Bioinformatics. 2016;32(19):3012–4.
doi: 10.1093/bioinformatics/btw325
pubmed: 27288499
pmcid: 5039916
Therneau TM, until 2009) TL (original S >R port and R maintainer, Elizabeth A, Cynthia C. survival: Survival Analysis [Internet]. 2023 [cited 2023 Oct 6]. Available from: https://cran.r-project.org/web/packages/survival/index.html
Rossi S, Barresi S, Stracuzzi A, Lopez-Nunez O, Chiaravalli S, Ferrari A, et al. DICER1-associated malignancies mimicking germ cell neoplasms: report of two cases and review of the literature. Pathol - Res Pract. 2021;1(225): 153553.
doi: 10.1016/j.prp.2021.153553
Hornick JL, Nielsen GP. Beyond “Triton”: malignant peripheral nerve sheath tumors with complete heterologous rhabdomyoblastic differentiation mimicking spindle cell rhabdomyosarcoma. Am J Surg Pathol. 2019;43(10):1323.
doi: 10.1097/PAS.0000000000001290
pubmed: 31107719
Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40(5):499–507.
doi: 10.1038/ng.127
pubmed: 18443585
pmcid: 2912221
Agaram NP, Wexler LH, Chi P, Antonescu CR. Malignant peripheral nerve sheath tumor in children: a clinicopathologic and molecular study with parallels to the adult counterpart. Genes Chromosomes Cancer. 2023;62(3):131–8.
doi: 10.1002/gcc.23106
pubmed: 36414547
Kao YC, Sung YS, Zhang L, Huang SC, Argani P, Chung CT, et al. Recurrent BCOR internal tandem duplication and YWHAE-NUTM2B fusions in soft tissue undifferentiated round cell sarcoma of infancy – overlapping genetic features with clear cell sarcoma of kidney. Am J Surg Pathol. 2016;40(8):1009–20.
doi: 10.1097/PAS.0000000000000629
pubmed: 26945340
pmcid: 4942366
Coffin CM, Cassity J, Viskochil D, Lor Randall R, Albritton K. Non-neurogenic sarcomas in four children and young adults with neurofibromatosis type 1. Am J Med Genet A. 2004;127A(1):40–3.
doi: 10.1002/ajmg.a.20651
pubmed: 15103715
Tomassen T, Kester LA, Tops BB, Driehuis E, van Noesel MM, van Ewijk R, et al. Loss of H3K27me3 occurs in a large subset of embryonal rhabdomyosarcomas: immunohistochemical and molecular analysis of 25 cases. Ann Diagn Pathol. 2021;1(52): 151735.
doi: 10.1016/j.anndiagpath.2021.151735
Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol. 2017;67:1–10.
doi: 10.1016/j.humpath.2017.05.010
pubmed: 28551330
pmcid: 5628119
Fine SW, McClain SA, Li M. Immunohistochemical staining for calretinin is useful for differentiating schwannomas from neurofibromas. Am J Clin Pathol. 2004;122(4):552–9.
doi: 10.1309/AGBGTBRJ4W0BC7LN
pubmed: 15487453
Kresbach C, Dottermusch M, Eckhardt A, Ristow I, Paplomatas P, Altendorf L, et al. Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities. Neuro-Oncol. 2023;25(9):1644–55.
doi: 10.1093/neuonc/noad053
pubmed: 36866403
Endo M, Kobayashi C, Setsu N, Takahashi Y, Kohashi K, Yamamoto H, et al. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011;17(11):3771–82.
doi: 10.1158/1078-0432.CCR-10-2393
pubmed: 21262917
Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Møller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 Is associated with CDKN2A/p16 inactivation. Am J Pathol. 1999;155(6):1879.
doi: 10.1016/S0002-9440(10)65507-1
pubmed: 10595918
pmcid: 1866954
Meehan RR, Pennings S. Shoring up DNA methylation and H3K27me3 domain demarcation at developmental genes. EMBO J. 2017;36(23):3407–8.
doi: 10.15252/embj.201798498
pubmed: 29167195
pmcid: 5709771
Antonescu CR. Emerging soft tissue tumors with kinase fusions: An overview of the recent literature with an emphasis on diagnostic criteria. Genes Chromosomes Cancer. 2020;59(8):437–44.
doi: 10.1002/gcc.22846
pubmed: 32243019
pmcid: 8323076
Tauziède-Espariat A, Duchesne M, Baud J, Le Quang M, Bochaton D, Azmani R, et al. NTRK-rearranged spindle cell neoplasms are ubiquitous tumours of myofibroblastic lineage with a distinct methylation class. Histopathology. 2023;82(4):596–607.
doi: 10.1111/his.14842
pubmed: 36413100
Hiemcke-Jiwa LS, Meister MT, Martin E, Dierselhuis MP, Haveman LM, Meijers RWJ, et al. NTRK rearrangements in a subset of NF1-related malignant peripheral nerve sheath tumors as novel actionable target. Acta Neuropathol (Berl). 2023;145(1):149–52.
doi: 10.1007/s00401-022-02515-3
pubmed: 36331594